Health Care·Pharmaceuticals·$4.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.16 | N/A | -12.57% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.16 | N/A | -12.57% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding the current market environment. They highlighted the importance of maintaining a long-term perspective.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite current performance.
There were no specific updates on product pipelines or market conditions.
Corcept Therapeutics reported a lower-than-expected EPS for Q3-2025, leading to a 4.14% decline in stock price. The lack of revenue data and guidance contributed to investor uncertainty. Management's cautious tone suggests they are navigating challenges without immediate solutions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Nov 3, 2025